^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Thyroid Gland Papillary Carcinoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Excerpt:
    ZELBORAF is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

    Excerpt:
    ...BRAF V600E mutation detected in the primary tumor or the recurrent/persistent tumor....
    Trial ID:
    NCT01709292
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

    Excerpt:
    ...- Confirmation in a CLIA certified laboratory or in an FDA-approved assay that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600....
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379

    Excerpt:
    ...- Confirmation in a CLIA certified laboratory or in an FDA-approved assay that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600....
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Clin Endocrinol Metab
    Title:

    Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience

    Excerpt:
    Vemurafenib is a potentially effective and well-tolerated treatment strategy in patients with advanced PTC harboring the BRAF(V600E) mutation.
    DOI:
    10.1210/jc.2014-2246
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Case Rep Oncol
    Title:

    Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib

    Excerpt:
    "The patient's PTC underwent a comprehensive genomic profile and was identified as harboring BRAF V600E. She started with 960 mg of vemurafenib twice daily...Two months later, repeat PET imaging demonstrated a dramatic reduction in both 18F-fluorodeoxyglucose avidity and mass size...
    DOI:
    10.1159/000363377
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    J Transl Med
    Title:

    Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies

    Published date:
    01/09/2023
    Excerpt:
    Drug sensitivity assays of PTC organoid cultures demonstrated the intra- and inter-patient specific drug responses. BRAFV600E inhibitors, vemurafenib and dabrafenib monotherapy was mildly effective in treating BRAFV600E-mutant PTC organoids.
    DOI:
    10.1186/s12967-022-03848-z